Literature DB >> 26595078

Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide.

L Castagna1, S Bramanti1, S Furst2, L Giordano3, B Sarina1, R Crocchiolo1, J El-Cheikh, J El Cheikh2, A Granata2, L Morabito1, E Mauro4, C Faucher2, B Mohty2, S Harbi2, R Devillier2, C Chabannon5,6,7, C Carlo-Stella1, A Santoro1, D Blaise2,6,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26595078     DOI： 10.1038/bmt.2015.289

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  14 in total

1.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.

Authors:  Madan Jagasia; Mukta Arora; Mary E D Flowers; Nelson J Chao; Philip L McCarthy; Corey S Cutler; Alvaro Urbano-Ispizua; Steven Z Pavletic; Michael D Haagenson; Mei-Jie Zhang; Joseph H Antin; Brian J Bolwell; Christopher Bredeson; Jean-Yves Cahn; Mitchell Cairo; Robert Peter Gale; Vikas Gupta; Stephanie J Lee; Mark Litzow; Daniel J Weisdorf; Mary M Horowitz; Theresa Hahn
Journal:  Blood       Date:  2011-10-18       Impact factor: 22.113

2.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

3.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

4.  Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies.

Authors:  Paolo Di Bartolomeo; Stella Santarone; Gottardo De Angelis; Alessandra Picardi; Laura Cudillo; Raffaella Cerretti; Gaspare Adorno; Stefano Angelini; Marco Andreani; Lidia De Felice; Maria Cristina Rapanotti; Loredana Sarmati; Pasqua Bavaro; Gabriele Papalinetti; Marta Di Nicola; Franco Papola; Mauro Montanari; Arnon Nagler; William Arcese
Journal:  Blood       Date:  2012-11-19       Impact factor: 22.113

5.  Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.

Authors:  R A Nash; J H Antin; C Karanes; J W Fay; B R Avalos; A M Yeager; D Przepiorka; S Davies; F B Petersen; P Bartels; D Buell; W Fitzsimmons; C Anasetti; R Storb; V Ratanatharathorn
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

Review 6.  Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation.

Authors:  P Jacobson; J Uberti; W Davis; V Ratanatharathorn
Journal:  Bone Marrow Transplant       Date:  1998-08       Impact factor: 5.483

7.  Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan.

Authors:  M Yanada; N Emi; T Naoe; H Sakamaki; S Takahashi; N Hirabayashi; A Hiraoka; Y Kanda; R Tanosaki; S Okamoto; K Iwato; Y Atsuta; N Hamajima; M Tanimoto; S Kato
Journal:  Bone Marrow Transplant       Date:  2004-08       Impact factor: 5.483

8.  Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.

Authors:  Kyoo-Hyung Lee; Je-Hwan Lee; Jung-Hee Lee; Dae-Young Kim; Se-Hyung Kim; Ho-Jin Shin; Young-Shin Lee; Young-Ah Kang; Miee Seol; Sung-Gil Ryu
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

Review 9.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

10.  Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.

Authors:  V Ratanatharathorn; R A Nash; D Przepiorka; S M Devine; J L Klein; D Weisdorf; J W Fay; A Nademanee; J H Antin; N P Christiansen; R van der Jagt; R H Herzig; M R Litzow; S N Wolff; W L Longo; F B Petersen; C Karanes; B Avalos; R Storb; D N Buell; R M Maher; W E Fitzsimmons; J R Wingard
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113
View more
  3 in total

1.  A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation.

Authors:  Nelli Bejanyan; Joseph A Pidala; Xuefeng Wang; Ram Thapa; Taiga Nishihori; Hany Elmariah; Aleksandr Lazaryan; Farhad Khimani; Marco L Davila; Asmita Mishra; Rawan Faramand; Michael D Jain; Leonel Ochoa; Lia Elena Perez; Hien Liu; Melissa Alsina; Mohamed A Kharfan-Dabaja; Hugo Fernandez; Michael L Nieder; Frederick L Locke; Claudio Anasetti; Ernesto Ayala
Journal:  Blood Adv       Date:  2021-03-09

2.  Risk factors for adverse outcomes following haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide: a two-center analysis.

Authors:  Viviane Jesus Torres de Lima; Anderson Felipe da Silva; Lucila Nassif Kerbauy; Mariana Nassif Kerbauy; Decio Lerner; Marta Colares; Andreza Alice Feitosa Ribeiro; Cinthya Feitosa da Silva; Nelson Hamerschlak; Leonardo Javier Arcuri
Journal:  Ann Hematol       Date:  2022-05-16       Impact factor: 4.030

Review 3.  Immunosenescence in Childhood Cancer Survivors and in Elderly: A Comparison and Implication for Risk Stratification.

Authors:  Petra Lázničková; Kamila Bendíčková; Tomáš Kepák; Jan Frič
Journal:  Front Aging       Date:  2021-07-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.